Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Sesen Bio, Inc. (NasdaqCM: SESN) (the “Company”) with Carisma Therapeutics Inc., pursuant to which pre-merger Sesen Bio shareholders are expected to own approximately 41.7% of the combined company, subject to adjustment. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqcm-sesn/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220921006043/en/